icon star paper   Hepatitis B Articles (HBV)  
Back grey_arrow_rt.gif
New HBV Drugs / New /HBV-Cyclophillin Inhibitor
  Curing HBV, New Drugs - (01/22/15)
"in order to effectively clear an HBV infection and produce full remission, the viral cccDNA intermediates need to be destroyed"
"........any CURE of chronic hepatitis B will require elimination of cccDNA......cccDNA - HBV's largely unexplored persistence reservoir....." Jurgen Beck's talk see slide set in link above"
AASLD: Curing HBV....attacking cccDNA "Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease" - (01/12/15)
Antiviral Therapy for Chronic Hepatitis B Reduces the Incidence of Hepatocellular Carcinoma Regardless of Cirrhosis Status: Analysis with Adjustment for REACH-B Risk Score - (12/21/15)
Johnson & Johnson Announces Completion Of Novira Therapeutics, Inc. Acquisition - (12/21/15)
New HBV Drug Cyclophilin inhibitor CPI-431-32 in Pre-Clinical Development
MORE HBV Research
AASLD: Antiviral Activity of TAF Against Drug-Resistant HBV Isolates in Vitro - (01/07/16)
Gilead Announces Top-Line Results From Two Phase 3 Studies Evaluating Tenofovir Alafenamide (TAF) for Patients With Chronic Hepatitis B Infection - (01/05/16)
AASLD: Safety and Pharmacodynamics of Oral TLR-7 Agonist GS-9620 in Patients With Chronic Hepatitis B - (12/21/15)
AASLD: Functional Activation of Natural Killer and CD8+ T Cells by the Toll-Like Receptor 7 Agonist GS-9620 - (12/21/15)
AASLD: Cytokines Induced by a Toll-Like Receptor 7 Agonist Potently Inhibit HBV RNA, DNA, and Antigen Levels in Primary Human Hepatocytes - (12/21/15)
AASLD: Safety and Efficacy of GS-4774 in Patients With Chronic Hepatitis B on Oral Antiviral Therapy - (12/22/15)
AASLD: Tenofovir Disoproxil Fumarate Reduces Perinatal Transmission of Hepatitis B Virus in Highly Viremic Mothers: A Multicenter Randomized Controlled Study - (12/18/15)
AASLD: Integrated HBV DNA implicated in maintaining circulating HBsAg levels in chronically infected chimpanzees - (12/02/15)
AASLD: Monthly dosing of ARC-520 in chronically hepatitis B virus infected chimpanzees produces rapid, deep and durable reductions in circulating viral antigens - (12/02/15)
AASLD: Arrowhead Late-Breaking Clinical Data Shows that ARC-520 Can Produce Deep and Durable Reductions of Hepatitis B Viral Antigens and DNA - (12/02/15)
AASLD: ARC-520 produces deep and durable knockdown of viral antigens and DNA in a phase II study in patients with chronic hepatitis B - (12/02/15)
AASLD: Encapsidation and secretion of HBV RNA can be inhibited by Core Inhibitors but not by Nucleoside Analogs [NVR 3-778] - (12/02/15)
AASLD: Phase 1b Efficacy and Safety of NVR 3-778, a First-In-Class HBV Core Inhibitor, in HBeAg-Positive Patients with Chronic HBV Infection - (12/02/15)
AASLD: Inhibition of Hepatitis B Virus Replication by the HBV Core Inhibitor NVR 3-778 - (12/02/15)
Transgene Announces Dosing of First Patient with TG1050 for Treatment of Chronic Hepatitis B Infection - (11/05/15)

  icon paper stack View Older Articles   Back to Top   www.natap.org